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lyze germline-derived data from 402 patients with 
differentiated thyroid carcinoma. We used these 
data, which were made available by the Cancer 
Genome Atlas (TCGA) Research Network,2 to as-
sess the contribution of known cancer-predispo-
sition genes3 to differentiated thyroid carcinoma.
No mutations were detected in PTEN, APC, or 
WRN. Instead, to our surprise, we identified 23 
patients (5.7%) with a truncating mutation in one 
of five DNA-repair genes: BRCA1 (in 1 patient), 
ATM (in 1), CHEK2 (in 4), MSH6 (in 4), and BRCA2 
(in 13). These findings suggest a role for DNA-
repair genes in susceptibility to differentiated 
thyroid carcinoma, but additional deleterious 
somatic mutations in these genes were not seen 
in the associated tumors. Studies have identified 
an excess of differentiated thyroid carcinoma in 
CHEK2 mutation carriers,4 but not in BRCA2 hetero-
zygotes.5 Further investigations to clarify the clini-
cal significance of these findings are warranted.
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The authors reply: In reply to Fahiminiya and 
associates: epidemiologic studies show that some 
papillary thyroid carcinomas are heritable, and 
genomewide association studies have identified 
variants conferring predisposition to papillary 
thyroid carcinoma, although their functional 
consequences have not been fully elucidated.1-3 In 
response to our article, in which we described 
germline events predisposing to papillary thy-
roid carcinoma, Fahiminiya and colleagues ana-
lyzed germline data from a TCGA study involving 
patients with papillary thyroid carcinoma, and they 
identified truncation mutations in DNA-repair 
genes in 23 of 402 patients (5.7%). This poten-
tially important observation has not yet been 
confirmed.
Somatic mutations of DNA damage–response 
genes, including CHEK2 and PPM1D, were detect-
ed in high-risk papillary thyroid carcinoma tu-
mors from the series in TCGA. Indeed, muta-
tions of this class of genes are also enriched in 
poorly differentiated and anaplastic thyroid car-
cinomas.4 Although current evidence points to a 
multifactorial genetic predisposition to papillary 
thyroid carcinoma, these findings may warrant 
a reappraisal of the role of DNA-repair genes in 
susceptibility to papillary thyroid carcinoma, par-
ticularly in vulnerable populations such as chil-
dren who have been exposed to ionizing radiation.
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Efficacy of Convalescent Plasma in Relation to Dose of Ebola 
Virus Antibodies
To the Editor: We previously reported the re-
sults of a nonrandomized, controlled trial that 
compared survival among patients with Ebola 
virus (EBOV) disease who were treated with con-
valescent plasma with survival among historical 
controls. Although no safety concerns were iden-
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Figure 1. Titers of Total IgG and Neutralizing Antibodies against the Ebola Virus (EBOV) in Plasma from Convalescent Donors, Distribution 
of Total-Antibody Doses Given to Patients, Odds Ratios for Death between Days 3 and 16, and Changes in Cycle-Threshold Value after 
Transfusion.
Panel A shows the distribution of titers of total anti‑EBOV IgG and neutralizing antibodies against EBOV in 85 donations from 58 con‑
valescent donors whose plasma was used in the trial. ND denotes not detected. Panel B shows the distribution of the total dose of anti‑
bodies administered to patients with EBOV disease. To calculate the total dose that a patient received, the volume of the plasma unit 
was multiplied by the corresponding optical‑density value from the enzyme‑linked immunosorbent assay (for total anti‑EBOV IgG) or 
antibody titer (for neutralizing antibodies); the sum of this measure for all plasma units that a patient received represented the estimated 
total‑antibody dose. The total dose of neutralizing antibodies has been divided by a factor of 10. Infused plasma in which no antibodies 
were detected were allocated a zero dose in the estimation of the total dose. The dashed lines show the cutoff for the lowest‑dose group 
of estimated antibody dose, and the corresponding solid lines show the cutoff for the middle‑dose group (Spearman’s rho = 0.425; P<0.001). 
Panel C shows the adjusted odds ratio for death between days 3 and 16 after diagnosis among 71 patients 16 years of age or older. The 
analysis used the lowest‑dose group as the reference group, with adjustment for age and pretransfusion cycle‑threshold value. I bars in‑
dicate 95% confidence intervals. Patients who died before day 3 after the diagnosis of EBOV disease were excluded.1,2 In a test for asso‑
ciation assuming a linear trend, after adjustment for age and cycle threshold, P = 0.21 for IgG and P = 0.32 for neutralizing antibodies. 
Panel D shows the change in EBOV cycle‑threshold values from before to after transfusion among 83 patients 16 years of age or older. 
The analysis used the lowest‑dose group as the reference group, with adjustment for age and pretransfusion cycle‑threshold value. The 
cycle‑threshold value is the number of cycles required for the fluorescence signal to cross the threshold for a positive result on the EBOV 
polymerase‑chain‑reaction assay; lower values indicate higher viral loads. I bars indicate 95% confidence intervals. More patients were 
included in this analysis than in the mortality analysis (see the Supplementary Appendix). In tests for heterogeneity between the dose 
groups (with adjustment for age and pretransfusion cycle‑threshold value), P = 0.02 for IgG and P = 0.82 for neutralizing antibodies. In a 
test for a linear trend (with adjustment for age and pretransfusion cycle‑threshold values), P = 0.06 for IgG and P = 0.69 for neutralizing 
antibodies.
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tified, efficacy was not shown.1 Notably, the levels 
of total anti-EBOV IgG and neutralizing antibod-
ies in the infused plasma were unknown at the 
time of administration.1,2 We now report on the 
association between the amount of total anti-
EBOV IgG and neutralizing antibodies received 
and patient survival and on the changes in the 
amount of EBOV in their blood 24 hours after 
transfusion, expressed as the change in the cycle-
threshold value in the polymerase-chain-reaction 
(PCR) analysis. The cycle-threshold value is the 
number of cycles required for the f luorescence 
signal to cross the threshold for a positive result 
on the EBOV PCR assay; lower values indicate 
higher viral loads.
The level of antibodies in the 85 donations was 
determined by means of an enzyme-linked immu-
nosorbent assay (ELISA) and a plaque-neutraliza-
tion assay (see the Supplementary Appendix, avail-
able with the full text of this letter at NEJM.org). 
ELISA titers for 94% of the donations were at 
least 1:1000. In the 50% plaque-neutralizing ac-
tivity assay, most donations (75%) had a titer of 
1:10 or 1:40, and only 4 (5%) had a titer of 1:160 
(Fig. 1A). For each patient, a total-antibody dose 
was calculated by multiplying the volume of 
convalescent plasma infused by the EBOV anti-
body titer in the donation. The analysis was re-
stricted to adults, because the dosing of conva-
lescent plasma was done differently in children.
Patients were categorized into one of three 
equally sized groups on the basis of the esti-
mated total-antibody dose (Fig. 1B). By chance, 
the pretransfusion cycle-threshold values were 
lowest in the highest-dose group for IgG and in 
the middle-dose group for neutralizing antibod-
ies, and there was significant imbalance in the 
neutralizing-antibodies dose groups (see the Sup-
plementary Appendix). Adjusting for age and pre-
transfusion cycle-threshold value, we observed 
lower mortality with higher IgG doses and higher 
mortality with higher doses of neutralizing anti-
bodies, but neither of these associations was 
significant (Fig. 1C). The change in cycle-thresh-
old values from before to after transfusion dif-
fered significantly according to IgG dose group 
(P = 0.02). However, there was little difference 
between the two higher-dose groups (Fig. 1D) 
and only weak evidence of a linear trend overall 
(P = 0.06). No association was apparent with the 
dose of neutralizing antibodies.
In conclusion, most patients received plasma 
with anti-EBOV IgG antibodies, but levels of neu-
tralizing antibodies were low in many donations. 
The dose of IgG antibodies showed an associa-
tion with larger increases in cycle-threshold val-
ues after transfusion but no significant associa-
tion with mortality. Neither outcome showed an 
association with the estimated doses of neutral-
izing antibodies received. Further studies are 
needed to assess the effectiveness of an antibody 
dose higher than the doses used in this study, 
the antibody measure that best correlates with 
virologic and clinical outcomes, and the poten-
tial mechanism and clinical effect of viral clear-
ance by anti-EBOV IgG antibodies.
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